Host factors may influence response to antiviral therapy in chronic hepatitis B virus infections

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 417-420

  Schildgen, Oliver ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOSIDE DIPHOSPHATE KINASE; PROTEIN X; TENOFOVIR; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; HOST RESISTANCE; HYPOTHESIS; NONHUMAN; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; VIRUSES;

HEPATITIS B VIRUS;

EID: 79751538342     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.11.007     Document Type: Article

References (39)

1. Liaw Y.F. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006, 11:669-679.
2. Liu C.J., et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006, 193:1258-1265.
3. Hadziyannis S.J. New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther 2006, 6:913-921.
4. Potthoff A., et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat 2006, 13:734-741.
5. Schildgen O., Helm M., Gerlich W. Nonresponse to adefovir: host or virus dependent?. J Clin Virol 2006, 37:327-328.
6. Tillmann H.L. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007, 13:125-140.
7. Schildgen O. Novel lamivudine resistance. Antimicrob Agents Chemother 2007, 51:4533-4544.
8. Schildgen O., Hartmann H., Gerlich W.H. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol 2006, 41:245-246.
9. Schildgen O., et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. Aids 2004, 18:2325-2327.
10. Schildgen O., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 354:1807-1812.
11. Sirma H., Funk A., Gerlich W., Schildgen O. Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?. J Antimicrob Chemother 2007, 60:448-449.
12. Carrouee-Durantel S., et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008, 13:381-388.
13. Curtis M., Zhu Y., Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 2007, 196:1483-1486.
14. Durantel D., et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005, 34(Suppl. 1):S34-S43.
15. Villet S., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48:747-755.
16. Ray A.S., Vela J.E., Olson L., Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem Pharmacol 2004, 68:1825-1831.
17. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006, 112:457-473.
18. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007, 1775:237-262.
19. Cihlar T., Rosenberg I., Votruba I., Holy A. Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated. Antimicrob Agents Chemother 1995, 39:117-124.
20. Balzarini J., Perno C.F., Schols D., De Clercq E. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun 1991, 178:329-335.
21. Krejcova R., Horska K., Votruba I., Holy A. Interaction of guanine phosphonomethoxyalkyl derivatives with GMP kinase isoenzymes. Biochem Pharmacol 2000, 60:1907-1913.
22. Robbins B.L., Connelly M.C., Marshall D.R., Srinivas R.V., Fridland A. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol 1995, 47:391-397.
23. Robbins B.L., Greenhaw J., Connelly M.C., Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 1995, 39:2304-2308.
24. Delaney W.E.T., et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006, 50:2471-2477.
25. Lipskaya T.Y., Voinova V.V. Functional coupling between nucleoside diphosphate kinase of the outer mitochondrial compartment and oxidative phosphorylation. Biochemistry (Mosc) 2005, 70:1354-1362.
26. Lipskaya T.Y., Voinova V.V. Mitochondrial nucleoside diphosphate kinase: mode of interaction with the outer mitochondrial membrane and proportion of catalytic activity functionally coupled to oxidative phosphorylation. Biochemistry (Mosc) 2008, 73:321-331.
27. Tokarska-Schlattner M., et al. The nucleoside diphosphate kinase D (NM23-H4) binds the inner mitochondrial membrane with high affinity to cardiolipin and couples nucleotide transfer with respiration. J Biol Chem 2008, 283:26198-26207.
28. McKenzie M., Lazarou M., Thorburn D.R., Ryan M.T. Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. J Mol Biol 2006, 361:462-469.
29. Stroh A., et al. Assembly of respiratory complexes I, III, and IV into NADH oxidase supercomplex stabilizes complex I in Paracoccus denitrificans. J Biol Chem 2004, 279:5000-5007.
30. Desai V.G., et al. Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver. Mitochondrion 2008, 8:181-195.
31. Bouchard M.J., Wang L.H., Schneider R.J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001, 294:2376-2378.
32. Clippinger A.J., Bouchard M.J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol 2008, 82:6798-6811.
33. Chen J., Siddiqui A. Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. J Virol 2007, 81:6757-6760.
34. Angus P., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
35. Lucifora J., et al. Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J Gen Virol 2008, 89:1819-1828.
36. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006, 26:171-180.
37. Wong S.N., Lok A.S. Treatment of hepatitis B: who, when, and how?. Arch Intern Med 2006, 166:9-12.
38. Das K., et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001, 75:4771-4779.
39. Langley D.R., et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007, 81:3992-4001.